Vincerx Pharma Faces Delisting Concerns

TL;DR

Vincerx Pharma might get kicked off the exchange - big trouble.

AI Summary

Vincerx Pharma, Inc. filed an 8-K on November 25, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, previously known as LifeSci Acquisition Corp., is based in Palo Alto, California.

Why It Matters

This filing indicates potential issues with Vincerx Pharma's continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to trade publicly, posing a significant risk to its operations and investors.

Key Numbers

• 001-39244 — SEC File Number (Identifies the company's filing with the SEC.)
• 83-3197402 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Vincerx Pharma, Inc. (company) — Registrant
• LifeSci Acquisition Corp. (company) — Former company name
• November 25, 2024 (date) — Date of report
• 260 Sheridan Avenue, Suite 400 (address) — Principal executive offices
• Palo Alto, California (location) — Principal executive offices location

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VINC The Nasdaq
• $1.00 — an the minimum bid price requirement of $1.00 per share. The Company had 180 calendar

Filing Documents

• d851139d8k.htm (8-K) — 24KB
• 0001193125-24-265244.txt ( ) — 147KB
• vinc-20241125.xsd (EX-101.SCH) — 3KB
• vinc-20241125_lab.xml (EX-101.LAB) — 18KB
• vinc-20241125_pre.xml (EX-101.PRE) — 11KB
• d851139d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 260 Sheridan Avenue , Suite 400 Palo Alto , California 94306 (Address of principal executive offices) (Zip Code) (650) 800-6676 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share VINC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on May 22, 2024, Vincerx Pharma, Inc. (the "Company") received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the Company's common stock for the prior 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share. The Company had 180 calendar days, or by November 18, 2024, to regain compliance with the minimum bid price requirement but could be eligible for an additional 180-day compliance period. On November 14, 2024, the Company submitted a request to Nasdaq for an additional 180-day extension to regain compliance with the minimum bid price requirement. On November 19, 2024, the Company received a letter from Nasdaq advising that the Company had been granted an additional 180-day extension, or until May 19, 2025, to regain compliance with the minimum bid price requirement. The Company will continue to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including implementing a reverse stock split of its outstanding common stock, to regain compliance with the minimum bid price requirement. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement during this 180-day extension or meet the other continued listing requirements of The Nasdaq Capital Market. If the Company does not regain compliance within the additional compliance period, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel, although there can be no assurance that such an appeal would be successful. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 25, 2024 VINCERX PHARMA, INC. By: /s/ Alexander A. Seelenberger Name: Alexander A. Seelenberger Title: Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR